Cover Image

Denosumab Offers Relatively Lower Initial Protection Against Osteoporotic Vertebral Fractures in Treatment‐Naive Patients Compared With Zoledronate

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Ko‐Hsiu Lu, Shiow‐Ing Wang, Shun‐Fa Yang
Format:	Artículo Open Access
Published:	Wiley 2026
Subjects:	Clinical Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Discontinuing Long‐Term Denosumab in Treating Fragile Bone: Why, for Whom, and How?
by: Ko‐Hsiu Lu, et al.
Published: (2026)

Therapeutic Strategies of Denosumab Sequential Therapy: A Four‐Armed Randomized Controlled Trial
by: Hung‐Kuan Yen, et al.
Published: (2025)

The Impact of QT‐Prolonging Medications and Drug–Drug Interactions on QTc Interval Prolongation in Hospitalized Patients: A Case‐Crossover Study
by: Hsiu‐Ting Chien, et al.
Published: (2024)

Liberty on Odaiba, Against the Silhouette of Tokyo Bay: Inspirations for Moving Hypothesis‐Generating Research to Patient‐Centered Therapeutics
by: Karthik Venkatakrishnan
Published: (2026)

Predicting Survival in Patients with Advanced NSCLC Treated with Atezolizumab Using Pre‐ and on‐Treatment Prognostic Biomarkers
by: Sébastien Benzekry, et al.
Published: (2024)

Folinic Acid Prophylaxis and Dose Adjustments Enable Safe Treatment with Pemetrexed in Patients with Renal Impairment
by: Nikki de Rouw, et al.
Published: (2025)

Comparative Safety of Tenecteplase and Alteplase in Direct Oral Anticoagulant‐Pretreated Patients With Acute Ischemic Stroke
by: Hsu‐Wei Lin, et al.
Published: (2025)

Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Studies Related to Vincristine‐Induced Peripheral Neuropathy in Chinese Pediatric ALL Patients
by: Yawen Yuan, et al.
Published: (2024)

Comparative Safety of Long‐Acting vs. Short‐Acting Erythropoiesis‐Stimulating Agents Among Patients Undergoing Hemodialysis
by: Raj Desai, et al.
Published: (2024)

Using Machine Learning to Determine a Suitable Patient Population for Anakinra for the Treatment of COVID‐19 Under the Emergency Use Authorization
by: Qi Liu, et al.
Published: (2024)

Tocilizumab Dosing for Management of T Cell‐Engaging Bispecific Antibody‐Related CRS in Patients With R/R B‐Cell NHL
by: Candice Jamois, et al.
Published: (2025)

US Food and Drug Administration's Advancing Real‐World Evidence Program: Initial Experience
by: Kimberly A. Smith, et al.
Published: (2025)

Aging‐Related CYP3A Functional Changes in Chinese Older Patients: New Findings from Model‐Based Assessment of Amlodipine
by: Jie En Valerie Sia, et al.
Published: (2024)

Model‐Informed Drug Development‐Based Approval of Intravenous Secukinumab for the Treatment of Adult Patients with Active Psoriatic Arthritis, Active Ankylosing Spondylitis, and Active Non‐Radiographic Axial Spondyloarthritis
by: Dipak S. Pisal, et al.
Published: (2024)

Background Factors Contributing to Safety Warning Discordance in the Initial Labeling of New Drugs in Japan, the United States, and the European Union
by: Koichi Fukuda, et al.
Published: (2024)

Challenging the Detection of Comedication Interactions Related to Immune‐Related Adverse Events Using Spontaneous Reporting Systems
by: Yuki Nakano
Published: (2025)

Using Machine Learning to Individualize Treatment Effect Estimation: Challenges and Opportunities
by: Alicia Curth, et al.
Published: (2024)

Ongoing Pharmacological Developments in SLC6A1 Research & Treatment
by: Melissa B. DeLeeuw, et al.
Published: (2024)

TMDD Modeling for Antibodies Directed Against Soluble Targets: Parameter Values for De Novo Modeling and Simulation From Experimental Data
by: Adam Nasim, et al.
Published: (2026)

Cerebral Ischemia Protection After Aneurysmal Subarachnoid Hemorrhage: CSF Nimodipine Levels After Intravenous Versus Oral Nimodipine Administration
by: Miriam M. Moser, et al.
Published: (2024)

Causal Effects of Hydrophilic Bile Acids on Carfilzomib‐Related Cardiovascular Events in Multiple Myeloma: A Mendelian Randomization Study
by: Samia Shabnaz, et al.
Published: (2026)

Optimal Drug, Optimal Dose, or Both in the Pharmacological Treatment of Neonatal Opioid Withdrawal Syndrome?
by: Walter K. Kraft
Published: (2025)

Agreement about Availability of Alternative Treatments for Innovative Drugs Assessed by the EMA and HTA Organizations
by: Jorge Madrid Paredes, et al.
Published: (2024)

The Promise of Health for All: A Collaborative Model to Close Treatment Gaps for Neglected Diseases
by: Delali Attipoe
Published: (2024)

A Randomized Trial Comparing Standard of Care to Bayesian Warfarin Dose Individualization
by: Ling Xue, et al.
Published: (2024)

Population Pharmacokinetic/Toxicodynamic Model for Polymyxin B in Critically Ill Patients to Identify the Risk of Nephrotoxicity
by: Patrick O. Hanafin, et al.
Published: (2025)

Patient Perceptions of and Experiences with Risk Evaluation and Mitigation Strategies
by: Ameet Sarpatwari, et al.
Published: (2025)

Exploring the Association Between Intra‐Patient Variability in Trough Concentration of Pazopanib and Clinical Outcomes in Renal Cell Carcinoma and Soft Tissue Sarcoma Patients
by: Amy Rieborn, et al.
Published: (2025)

FDA Approval Summary: Nalmefene Nasal Spray for the Emergency Treatment of Known or Suspected Opioid Overdose
by: Srikanth C. Nallani, et al.
Published: (2024)

Repurposing Acebutolol for Osteoporosis Treatment: Insights From Multi‐Omics and Multi‐Modal Data Analysis
by: Dan‐Yang Liu, et al.
Published: (2025)

Orphan Designation for Drugs Approved in the United States and European Union: A Comparative Analysis
by: Enrico Costa, et al.
Published: (2026)

Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma
by: Ruben Malmberg, et al.
Published: (2025)

CYP2C19 Genotype is Associated with Citalopram Treatment Outcomes in a Real‐World Setting
by: Yoomi Park, et al.
Published: (2026)

Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors
by: Alan Faraj, et al.
Published: (2024)

Population Pharmacokinetic and Exposure‐Efficacy Analysis of Baloxavir Marboxil for Influenza Treatment and Post‐Exposure Prophylaxis in Children
by: Sylvie Retout, et al.
Published: (2026)

Lower Dose‐Normalized Tacrolimus Exposure in CYP3A5 *6 vs. *3 Loss‐of‐Function Allele Carriers: A Longitudinal Retrospective Real‐World Study in Kidney Transplant Recipients
by: Amar D. Levens, et al.
Published: (2025)

Why Pediatric CAR ‐T Therapies Still Lag Behind: Insights from Six Treatments Centrally Approved in Europe
by: Lisa Hanquet, et al.
Published: (2026)

Association of Neurodevelopmental Disorders and Congenital Anomalies With Prenatal Multiple Sclerosis Treatment—Real‐World Historical Cohort Study
by: Bar Rosh, et al.
Published: (2026)

Optimal Trough Concentration of Tacrolimus in Pediatric Patients With Primary Nephrotic Syndrome
by: Hui Wang, et al.
Published: (2024)

Chat GPT and the Challenges to Detect Potential Drug–Drug Interactions Related to QT Prolongation
by: Emanuel Raschi, et al.
Published: (2025)